



Global Research & Development

9th July 2007

Regulatory Lead Women's Health/ Sex Health
Worldwide Regulatory Strategy - Europe
Direct Line: +44 1304 643071
Fax Line: +44 1304 655047
Email: Sylvia.lobo@pfizer.com

Information Processing Unit
Area 6 – Clinical Trial Applications and related
responses to RFIs
Medicines & Healthcare Products Regulatory Agency
Market Towers
1 Nine Elms Lane
London
SW8 5NQ

Dear Sir or Madam

**Notification: June 2007 Erratum to March 2007 Investigator's Brochure for
PF-00446687**

**Compound: PF-00446687 up to 2mg/mL Oral Solution
EudraCT Number: 2007-001036-31
Protocol Number: A8361011
Internal SAN Number: 5829**

**Protocol Title: A 2-Cohort, Multi-Centre, Randomized, Double Blind(3rd Party
Open), Placebo Controlled 4-Way Crossover Study to Assess the Efficacy of
Single Oral Doses of PF-00446687 on Erectile Function in Men Suffering From
Erectile Dysfunction, Using 100 mg Sildenafil As a Positive Control**

Please find enclosed a compact disc containing an erratum to the Investigator's
Brochure for the title compound.

The erratum relates to receptor-binding data for PF-00446687. No new data have
been included; the principal change is the removal of receptor data that have been
inadvertently included in one of the tables. The data are however, retained elsewhere
in the Investigator's Brochure in the appropriate table.

THIS DOCUMENT CONTAINS CONFIDENTIAL AND/OR TRADE SECRET INFORMATION THAT IS
DISCLOSED ONLY IN CONNECTION WITH THE LICENSING AND/OR REGISTRATION OF PRODUCTS FOR
PFIZER INC. OR ITS AFFILIATED COMPANIES. THIS DOCUMENT SHOULD NOT BE DISCLOSED OR USED, IN
WHOLE OR IN PART, FOR ANY OTHER PURPOSE WITHOUT THE PRIOR WRITTEN CONSENT OF PFIZER INC.

1

Page 1 of 2



Registered in England: No 526209
Registered Office: Ramsgate Road
Sandwich, Kent CT13 9NJ, UK

01000003700655\1.31\approved\08-Jul-2007 17:28



Global Research & Development

As the erratum has no impact on patient safety, this submission is in the form of a notification.

The erratum title page reference compound PF-0044687 – this is a typographical error as the correct compound reference is PF-00446687.

I trust that the above is satisfactory. However, please do not hesitate to contact me if I can be of further assistance.

Yours faithfully
For Pfizer Global Research & Development Limited



Worldwide Regulatory Strategy - Europe

Encl.: CD.

THIS DOCUMENT CONTAINS CONFIDENTIAL AND/OR TRADE SECRET INFORMATION THAT IS DISCLOSED ONLY IN CONNECTION WITH THE LICENSING AND/OR REGISTRATION OF PRODUCTS FOR PFIZER INC OR ITS AFFILIATED COMPANIES. THIS DOCUMENT SHOULD NOT BE DISCLOSED OR USED, IN WHOLE OR IN PART, FOR ANY OTHER PURPOSE WITHOUT THE PRIOR WRITTEN CONSENT OF PFIZER INC.

2

Page 2 of 2



REGISTERED TO PFIZER LIMITED

Registered in England: No 526209
Registered Office: Ramsgate Road
Sandwich, Kent CT13 9NJ, UK